CS208752B2 - Method of making the r-n-(2-fenyl-2-hydroxyethyl)-3-fenyl propylamines - Google Patents
Method of making the r-n-(2-fenyl-2-hydroxyethyl)-3-fenyl propylamines Download PDFInfo
- Publication number
- CS208752B2 CS208752B2 CS794628A CS462879A CS208752B2 CS 208752 B2 CS208752 B2 CS 208752B2 CS 794628 A CS794628 A CS 794628A CS 462879 A CS462879 A CS 462879A CS 208752 B2 CS208752 B2 CS 208752B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- hydroxyphenyl
- hydroxyethyl
- compounds
- hydrogen
- fenyl
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title description 4
- 125000006308 propyl amino group Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 3
- 229910052731 fluorine Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 5
- RGPGRFUHKBXJLQ-KRWDZBQOSA-N (1r)-1-phenyl-2-(3-phenylpropylamino)ethanol Chemical class C([C@H](O)C=1C=CC=CC=1)NCCCC1=CC=CC=C1 RGPGRFUHKBXJLQ-KRWDZBQOSA-N 0.000 abstract description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 239000011737 fluorine Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 206010019280 Heart failures Diseases 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- -1 amine salts Chemical class 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229950006768 phenylethanolamine Drugs 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960001089 dobutamine Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011418 maintenance treatment Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 2
- 240000001879 Digitalis lutea Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000022900 cardiac muscle contraction Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000010247 heart contraction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- IPMKAUAKEGAJNA-XSUJLISDSA-N solanapyrone g Chemical compound C1([C@H]2[C@@H]3CCCC[C@@H]3C=C[C@@H]2C)=CC(N)=C(C=O)C(=O)O1 IPMKAUAKEGAJNA-XSUJLISDSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MOMLUQUHQNAYEK-KRWDZBQOSA-N 3-[(1r)-1-hydroxy-2-[3-(4-hydroxyphenyl)propylamino]ethyl]phenol Chemical compound C([C@H](O)C=1C=C(O)C=CC=1)NCCCC1=CC=C(O)C=C1 MOMLUQUHQNAYEK-KRWDZBQOSA-N 0.000 description 1
- DPJAIQMVJHWZFH-KRWDZBQOSA-N 3-[3-[[(2R)-2-(2-fluorophenyl)-2-hydroxyethyl]amino]propyl]phenol Chemical compound O[C@@H](CNCCCC1=CC(O)=CC=C1)C1=C(F)C=CC=C1 DPJAIQMVJHWZFH-KRWDZBQOSA-N 0.000 description 1
- ILYGUWXQPRWYJO-KRWDZBQOSA-N 3-[3-[[(2r)-2-hydroxy-2-(3-hydroxyphenyl)ethyl]amino]propyl]phenol Chemical compound C([C@H](O)C=1C=C(O)C=CC=1)NCCCC1=CC=CC(O)=C1 ILYGUWXQPRWYJO-KRWDZBQOSA-N 0.000 description 1
- LEPIYBYPRPWIAA-UHFFFAOYSA-N 4-(propylamino)phenol Chemical compound CCCNC1=CC=C(O)C=C1 LEPIYBYPRPWIAA-UHFFFAOYSA-N 0.000 description 1
- ATSRSXZTAUWJAE-KRWDZBQOSA-N 4-[3-[[(2r)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]propyl]phenol Chemical compound C([C@H](O)C=1C=CC(O)=CC=1)NCCCC1=CC=C(O)C=C1 ATSRSXZTAUWJAE-KRWDZBQOSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- SBLCFSAWDQMCLB-LMOVPXPDSA-N CC1=CC=C(S([O-])(=O)=O)C=C1.C([C@H](O)C=1C=C(O)C=CC=1)[NH2+]CCCC1=CC=C(O)C=C1 Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C([C@H](O)C=1C=C(O)C=CC=1)[NH2+]CCCC1=CC=C(O)C=C1 SBLCFSAWDQMCLB-LMOVPXPDSA-N 0.000 description 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- JPYRAMGKAHVYFZ-CQSZACIVSA-N [(1r)-2-chloro-2-oxo-1-(3-phenylmethoxyphenyl)ethyl] 2,2-dichloroacetate Chemical compound ClC(Cl)C(=O)O[C@@H](C(Cl)=O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 JPYRAMGKAHVYFZ-CQSZACIVSA-N 0.000 description 1
- YTHUKBXVFYBAOR-LMOVPXPDSA-N [(2r)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]-[3-(3-hydroxyphenyl)propyl]azanium;2-methylpropanoate Chemical compound CC(C)C([O-])=O.C([C@H](O)C=1C=CC(O)=CC=1)[NH2+]CCCC1=CC=CC(O)=C1 YTHUKBXVFYBAOR-LMOVPXPDSA-N 0.000 description 1
- UKNHYPLORGBRMI-OOZXSOIMSA-N [(2r)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]-[3-(4-hydroxyphenyl)propyl]azanium;oxalate Chemical compound [O-]C(=O)C([O-])=O.C([C@H](O)C=1C=CC(O)=CC=1)[NH2+]CCCC1=CC=C(O)C=C1.C([C@H](O)C=1C=CC(O)=CC=1)[NH2+]CCCC1=CC=C(O)C=C1 UKNHYPLORGBRMI-OOZXSOIMSA-N 0.000 description 1
- HRULEIRZRYUMFB-LMOVPXPDSA-N [Cl-].FC1=C(C=CC=C1)[C@H](C[NH2+]CCCC1=CC=C(C=C1)O)O Chemical compound [Cl-].FC1=C(C=CC=C1)[C@H](C[NH2+]CCCC1=CC=C(C=C1)O)O HRULEIRZRYUMFB-LMOVPXPDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- QMUYXALROHDALD-UHFFFAOYSA-N n-benzyl-3-(3-phenylmethoxyphenyl)propan-1-amine Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1CCCNCC1=CC=CC=C1 QMUYXALROHDALD-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 150000008143 steroidal glycosides Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92166678A | 1978-07-03 | 1978-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS208752B2 true CS208752B2 (en) | 1981-09-15 |
Family
ID=25445781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS794628A CS208752B2 (en) | 1978-07-03 | 1979-07-02 | Method of making the r-n-(2-fenyl-2-hydroxyethyl)-3-fenyl propylamines |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0007716A1 (ro) |
| JP (1) | JPS559099A (ro) |
| AR (1) | AR221733A1 (ro) |
| AT (1) | ATA463879A (ro) |
| AU (1) | AU4848679A (ro) |
| BE (1) | BE877390A (ro) |
| CA (1) | CA1126296A (ro) |
| CS (1) | CS208752B2 (ro) |
| DD (1) | DD144764A5 (ro) |
| DK (1) | DK268479A (ro) |
| ES (2) | ES482152A1 (ro) |
| FI (1) | FI792078A7 (ro) |
| FR (1) | FR2430407A1 (ro) |
| GB (1) | GB2028801A (ro) |
| GR (1) | GR73049B (ro) |
| IL (1) | IL57669A0 (ro) |
| LU (1) | LU81454A1 (ro) |
| NZ (1) | NZ190862A (ro) |
| PH (1) | PH15477A (ro) |
| PL (1) | PL117485B1 (ro) |
| PT (1) | PT69842A (ro) |
| RO (1) | RO77727A (ro) |
| ZA (1) | ZA793294B (ro) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0103830A3 (de) * | 1982-09-22 | 1985-07-31 | Bayer Ag | Wachstumsfördernde Phenylethylamin-Derivate |
| EP0117647B1 (en) * | 1983-01-31 | 1988-08-17 | Eli Lilly And Company | Improvements in or relating to phenethanolamines |
| US4849453A (en) * | 1983-01-31 | 1989-07-18 | Eli Lilly And Company | Growth promotion |
| US5643967A (en) * | 1983-01-31 | 1997-07-01 | Eli Lilly And Company | Growth promotion |
| CN1073983C (zh) * | 1994-10-31 | 2001-10-31 | 中国科学院成都有机化学研究所 | 一种β－拟肾上腺素兴奋剂型饲料添加剂的合成方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6610530A (ro) * | 1966-07-27 | 1968-01-29 |
-
1979
- 1979-06-26 IL IL57669A patent/IL57669A0/xx unknown
- 1979-06-26 CA CA330,567A patent/CA1126296A/en not_active Expired
- 1979-06-26 DK DK268479A patent/DK268479A/da unknown
- 1979-06-27 NZ NZ190862A patent/NZ190862A/xx unknown
- 1979-06-27 PH PH22701A patent/PH15477A/en unknown
- 1979-06-28 PT PT69842A patent/PT69842A/pt unknown
- 1979-06-28 AU AU48486/79A patent/AU4848679A/en not_active Abandoned
- 1979-06-29 FR FR7916990A patent/FR2430407A1/fr active Granted
- 1979-07-02 GB GB7922954A patent/GB2028801A/en not_active Withdrawn
- 1979-07-02 LU LU81454A patent/LU81454A1/xx unknown
- 1979-07-02 JP JP8489379A patent/JPS559099A/ja active Pending
- 1979-07-02 EP EP79301281A patent/EP0007716A1/en not_active Withdrawn
- 1979-07-02 BE BE1/9441A patent/BE877390A/fr unknown
- 1979-07-02 CS CS794628A patent/CS208752B2/cs unknown
- 1979-07-02 FI FI792078A patent/FI792078A7/fi not_active Application Discontinuation
- 1979-07-02 RO RO7998008A patent/RO77727A/ro unknown
- 1979-07-02 GR GR59487A patent/GR73049B/el unknown
- 1979-07-03 AR AR277163A patent/AR221733A1/es active
- 1979-07-03 ZA ZA793294A patent/ZA793294B/xx unknown
- 1979-07-03 PL PL1979216813A patent/PL117485B1/pl unknown
- 1979-07-03 ES ES482152A patent/ES482152A1/es not_active Expired
- 1979-07-03 AT AT0463879A patent/ATA463879A/de not_active Application Discontinuation
- 1979-07-03 DD DD79214072A patent/DD144764A5/de unknown
-
1980
- 1980-04-01 ES ES490208A patent/ES8104188A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ES490208A0 (es) | 1981-04-16 |
| PT69842A (en) | 1979-07-01 |
| FI792078A7 (fi) | 1981-01-01 |
| PH15477A (en) | 1983-01-27 |
| AR221733A1 (es) | 1981-03-13 |
| EP0007716A1 (en) | 1980-02-06 |
| NZ190862A (en) | 1981-11-19 |
| PL117485B1 (en) | 1981-08-31 |
| ES8104188A1 (es) | 1981-04-16 |
| AU4848679A (en) | 1980-01-10 |
| IL57669A0 (en) | 1979-10-31 |
| GR73049B (ro) | 1984-01-26 |
| ES482152A1 (es) | 1980-08-16 |
| RO77727A (ro) | 1981-11-24 |
| JPS559099A (en) | 1980-01-22 |
| CA1126296A (en) | 1982-06-22 |
| FR2430407B1 (ro) | 1981-08-14 |
| BE877390A (fr) | 1980-01-02 |
| DK268479A (da) | 1980-01-04 |
| LU81454A1 (fr) | 1979-10-30 |
| PL216813A1 (ro) | 1980-03-24 |
| GB2028801A (en) | 1980-03-12 |
| FR2430407A1 (fr) | 1980-02-01 |
| ATA463879A (de) | 1981-10-15 |
| DD144764A5 (de) | 1980-11-05 |
| ZA793294B (en) | 1981-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0043807B1 (en) | 1-(dihydroxyphenyl)-2-amino-ethanol derivatives; preparation, compositions and intermediates | |
| EP0117779B1 (fr) | Dérivés de la pyridazine actifs sur le système nerveux central, procédé d'obtention et médicaments en contenant | |
| CS208664B2 (en) | Method of making the new r,s-n-/2-phenyl-2-hydroxyethyl/-1-alkyl-3-/4-substituted phenyl/propylamines | |
| CS266593B2 (en) | Method of 2-(2-hydroxy-3-phenosypropylamine) ethoxyphenolh's derivativesprodduction | |
| WO2013004190A1 (zh) | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 | |
| CS208660B2 (en) | Method of making the n-/2-phenyl-2-hydroxyethyl/-1,1-dimethyl-3-phenylpropylamin derivatives | |
| WO1999002512A1 (en) | Dl-2,3-diaryl-2h-1-benzopyrans | |
| WO1998027982A1 (en) | Composition containing ascorbic acid | |
| CS208752B2 (en) | Method of making the r-n-(2-fenyl-2-hydroxyethyl)-3-fenyl propylamines | |
| EP1257552B1 (fr) | Derives de xanthine, intermediaires et application au traitement de l'osteoporose | |
| EP0485583B1 (fr) | Utilisation de derives de la tetrahydro isoquinoleine pour la preparation de medicaments anti-tumoraux | |
| EP0133935A2 (de) | p-Oxibenzoesäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln mit hypolipämischer Wirkung | |
| JPS6334865B2 (ro) | ||
| EP2231603B1 (en) | Substituted 3 -hydroxypyridines and pharmaceutical compositions thereof | |
| EP0001021A2 (fr) | Nouveaux dérivés d'alcaloides pentacycliques, procédé de préparation, application à la synthèse de produits du groupe de l'éburnamonine et compositions pharmaceutiques | |
| FR2503705A1 (fr) | Derives de phenethanolamine, leur preparation et leur application en therapeutique | |
| JP2567593B2 (ja) | イミダゾリジントリオン誘導体及び該化合物を有効成分として含有するアレルギ−性疾患治療剤 | |
| JP2001503753A (ja) | アリールオキシプロパノールアミン誘導体、その製造方法及びその用途 | |
| US6201011B1 (en) | Therapeutic agent for allergic dermatitis | |
| US5958982A (en) | Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols | |
| WO2006007794A1 (en) | Cis-1,2-substituted stilbene derivates and the use thererof for manufacturing medicaments for treating medicaments for treating and/or preventing diabetes | |
| US20250205193A1 (en) | Therapeutic compound and salts | |
| EP0002638B1 (fr) | Sels d'addition d'aralkylamines subsituées et composition thérapeutique les contenant | |
| CS214706B2 (cs) | Způsob výroby R-jN-(2-fenyl-2-hydroxyethyl)-3-fenylpropylaminů | |
| JPS5865276A (ja) | 不整脈抑制性フエネチルピペリジン化合物 |